CYY-31357-61792
3 vaccinations
4 coded responses
35 check-ins
4 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 716 / AR
- Registered
- 2020-12-16
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-15
Dose 1 — Pfizer-BioNTech
-
2020-12-16
Registered in v-safe
- 2020-12-16
- 2020-12-17
-
2020-12-18
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Headache, Fatigue or tirednessAdult check-in
- 2020-12-19
- 2020-12-20
-
2020-12-21
Survey response — days 1–6 daily, dose 1MedDRA: Sinus congestion — Feeling: Fair · Headache, Fatigue or tirednessFree text: Sinus congestionMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2020-12-22
- 2020-12-29
-
2021-01-05
Dose 2 — Pfizer-BioNTech
- 2021-01-05
- 2021-01-06
- 2021-01-07
- 2021-01-08
- 2021-01-09
- 2021-01-19
- 2021-01-26
- 2021-02-02
- 2021-02-09
- 2021-02-16
-
2021-04-07
Survey response — 3 months, dose 2MedDRA: Condition aggravated, Electrocardiogram abnormal, Pre-existing disease, Reaction to previous exposure to any vaccine — Feeling: Good · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Emergency room or emergency department visit, HospitalizationFree text: First dose 12/15/20, had a prolonged episode of SVT on 12/26/20 ( > 24 hrs) This is a new condition, previously undiagnosed. Second dose 01/05/21. Another episode of SVT occurred on 03/20/21- diagnosed by EKG and started on medications.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-04-07
Report sent to call center — 3 months, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-09-28
Dose 3 — Pfizer-BioNTech
- 2021-09-28
- 2021-09-29
- 2021-09-30
- 2021-10-01
- 2021-10-02
- 2021-10-03
- 2021-10-04
- 2021-10-05
- 2021-10-12
- 2021-10-19
- 2021-10-26
- 2021-11-04
- 2021-11-11
- 2021-11-15
-
2021-12-28
Survey response — 3 months, dose 3MedDRA: Headache, Oropharyngeal pain, Rhinorrhoea, Sinus congestion — Feeling: Fair · Be unable to work or attend schoolFree text: Headache, sinus congestion, runny nose, sore throatMedDRA releases: 2024-11 · check-in free text available
- 2022-03-29
-
2022-09-28
Survey response — 12 months, dose 3MedDRA: Ageusia, Anosmia, COVID-19, Cough, Fatigue, Headache, Myalgia, Oropharyngeal pain, Pyrexia, Respiratory tract congestion — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: I contracted Covid over the summer and experienced congestion, significant fatigue, a cough, sore throat, fever, muscle aches, headache, and loss of taste and smell.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-15 | Pfizer-BioNTech | |
| 2 | 2021-01-05 | Pfizer-BioNTech | |
| 3 | 2021-09-28 | Pfizer-BioNTech | No |
Call center
1 call center case
1 unsuccessful
1 wait over 3 months for a first call
Free text
Release 1 — days 1–6 daily, dose 1
Systemic reaction (other): Sinus congestion
Release 7 — 3 months, dose 2
Symptoms: First dose 12/15/20, had a prolonged episode of SVT on 12/26/20 ( > 24 hrs) This is a new condition, previously undiagnosed. Second dose 01/05/21. Another episode of SVT occurred on 03/20/21- diagnosed by EKG and started on medications.
Release 10 — 3 months, dose 3
Symptoms: Headache, sinus congestion, runny nose, sore throat
Release 12 — 12 months, dose 3
Symptoms: I contracted Covid over the summer and experienced congestion, significant fatigue, a cough, sore throat, fever, muscle aches, headache, and loss of taste and smell.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Ageusia | · | · | ✓ |
| SD | Anosmia | · | · | ✓ |
| SD | Condition aggravated | ✓ | ✓ | ✓ |
| SD | Cough | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Electrocardiogram abnormal | ✓ | ✓ | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pre-existing disease | ✓ | ✓ | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Reaction to previous exposure to any vaccine | ✓ | ✓ | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | Sinus congestion | · | · | ✓ |
| SRO | Sinus congestion | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release